What we're reading, March 2, 2016: FDA commissioner pledges stronger efforts to develop harder-to-abuse painkillers; Olympus Corp. agrees to largest settlement for violating anti-kickback laws; and the Supreme Court hears Texas abortion case with just 8 members on the bench.
When the new FDA commissioner, Robert Califf, MD, was confirmed last week, it was over concerns from some senators that his agency had not done enough to combat the rising painkiller abuse epidemic. Now, Dr Califf is pledging to back efforts to develop painkillers that are harder to abuse, reported the AP. Since 2010, the FDA has approved 5 abuse-deterrent drugs and there are at least 30 similar drugs currently in development.
Olympus Corp. will pay $646 million to resolve probes into illegal kickbacks and bribes to doctors and hospitals. According to Kaiser Health News, the company, which is already under investigation for its role in superbug outbreaks, has used research grants, consulting deals, luxury trips and more to influence doctors to order more Olympus devices at hospitals. The company’s settlement is the largest ever for a kickback violation.
On Wednesday a closely watched abortion case went before the US Supreme Court. With only 8 justices on the bench, the court no longer has 5 conservatives who might support more restrictive abortion regulations nationwide, reported Reuters. The case focuses on whether a Texas law imposing strict regulations interferes with a woman’s constitutional right to end her pregnancy. If the court splits 4-4, the lower court’s ruling would stand, which would affirm the Texas law. The last time the Supreme Court ruled on an abortion case was 2007.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More